Immunocore Holdings (IMCR) Cost of Revenue (2022 - 2026)

Immunocore Holdings (IMCR) has reported Cost of Revenue for 5 consecutive years, with $434000.0 the latest figure, recorded in Q1 2026.

• Quarterly Cost of Revenue fell 47.77% year-over-year to $434000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.7 million (up 41.44% YoY) and the FY2025 annual result came in at $5.1 million, up 86.27% from the prior year.
• Cost of Revenue declined to $434000.0 in Q1 2026 per IMCR's latest filing, from $2.7 million in the prior quarter.
• Over the last five years, Cost of Revenue for IMCR reached as high as $2.7 million in Q4 2025 and fell as low as $74248.5 in Q3 2022.
• A 5-year average of $612775.5 and a median of $338000.0 in 2023 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2025 — Cost of Revenue surged 719.09% — and 2026, when it plunged 47.77%.
• Year by year, Cost of Revenue stood at $127849.2 in 2022, then jumped by 56.43% to $200000.0 in 2023, then soared by 65.0% to $330000.0 in 2024, then soared by 719.09% to $2.7 million in 2025, then tumbled by 83.94% to $434000.0 in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $434000.0, $2.7 million, and $513000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.